Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: Early late toxicity and 3-year clinical outcome

Radiotherapy and Oncology

Volumn 109, Issue 2, 2013, Pages 229-234

  Fonteyne, Valérie ^a   Lumen, Nicolaas ^a   Ost, Piet ^a   Van Praet, Charles ^a   Vandecasteele, Katrien ^a   De Gersem Ir, Werner ^a   Villeirs, Geert ^a   De Neve, Wilfried ^a   Decaestecker, Karel ^a   De Meerleer, Gert ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Lymph node positive prostate cancer; Outcome; Pelvic radiotherapy; Toxicity

Indexed keywords

BICALUTAMIDE;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER PATIENT; DISEASE SEVERITY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; KAPLAN MEIER METHOD; LINEAR ACCELERATOR; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION HAZARD; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

LYMPH NODE POSITIVE PROSTATE CANCER; OUTCOME; PELVIC RADIOTHERAPY; TOXICITY;

AGED; DOSE FRACTIONATION; GASTROINTESTINAL TRACT; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; PELVIS; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; UROGENITAL SYSTEM;

EID: 84889567770     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.08.006     Document Type: Article

References (32)

1. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74
2. R. Jacob, A.L. Hanlon, E.M. Horwitz, B. Movsas, R.G. Uzzo, and A. Pollack The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer Cancer 100 2004 538 543
3. D. Pucar, H. Hricak, and A. Shukla-Dave Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence Int J Radiat Oncol Biol Phys 69 2007 62 69
4. N. Pahlajani, K.J. Ruth, and M.K. Buyyounouski Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer Int J Radiat Oncol Biol Phys 82 2012 1949 1956
5. G. Arcangeli, J. Fowler, and S. Gomellini Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 79 2011 1013 1021
6. G. Arcangeli, B. Saracino, and S. Gomellini A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer Int J Radiat Oncol Biol Phys 78 2010 11 18
7. P. Sooriakumaran, L. Haendler, and T. Nyberg Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years Eur Urol 62 2012 768 774
8. N. Zamboglou, N. Tselis, and D. Baltas High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results Int J Radiat Oncol Biol Phys 85 2013 672 678
9. M.J. Zelefsky, H. Chan, M. Hunt, Y. Yamada, A.M. Shippy, and H. Amols Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer J Urol 176 2006 1415 1419
10. G.P. Swanson, I.M. Thompson, and J. Basler Treatment options in lymph node-positive prostate cancer Cancer 106 2006 2531 2539
11. V. Fonteyne, W. De Gersem, and W. De Neve Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer Int J Radiat Oncol Biol Phys 75 2009 1013 1020
12. J. Fowler, R. Chappell, and M. Ritter Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50 2001 1021 1031
13. V. Fonteyne, W. De Neve, G. Villeirs, C. De Wagter, and G. De Meerleer Late radiotehrapy-induced lower intestinal toxicity (RILIT) of intesity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity Radiother Oncol 84 2007 153 163
14. J.D. Cox, J. Stetz, and T.F. Pajak Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 5 1995 1341 1346
15. P. Ost, C. Cozzarini, and G. De Meerleer High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy Int J Radiat Oncol Biol Phys 83 2012 960 965
16. J.J. Coen, A.L. Zietman, H. Thakral, and W.U. Shipley Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases J Clin Oncol 20 2002 3199 3205
17. U. Zwergel, J. Lehmann, and B. Wullich Lymph node positive prostate cancer: long-term survival data after radical prostatectomy J Urol 171 2004 1128 1131
18. T. Cai, G. Nesi, and G. Tinacci Clinical importance of lymph node density in predicting outcome of prostate cancer patients J Surg Res 167 2011 267 272
19. L. Cheng, H. Zincke, M.L. Blute, E.J. Bergstralh, B. Scherer, and D.G. Bostwick Risk of prostate carcinoma death in patients with lymph node metastasis Cancer 91 2001 66 73
20. T.J. Robnett, R. Whittington, and S.B. Malkowicz Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer Int J Radiat Oncol Biol Phys 53 2002 1146 1151
21. A. Wang-Chesebro, P. Xia, J. Coleman, C. Akazawa, and M. Roach 3rd Intensity-modulated radiotehrapy imrproves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer Int J Radiat Oncol Biol Phys 66 2006 654 662
22. T. Guerrero Urbano, V. Khoo, and J. Staffurth Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study Clin Oncol 22 2010 236 244
23. P. Pommier, S. Chabaud, and J.L. Lagrange Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01 J Clin Oncol 25 2007 5366 5373
24. H. Quon, P.C. Cheung, and D.A. Loblaw Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity Int J Radiat Oncol Biol Phys 82 2012 898 905
25. M. Roach 3rd, M. DeSilvio, and R. Valicenti Whole-pelvis, "mini-pelvis", or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial Int J Radiat Oncol Biol Phys 66 2006 647 653
26. S. Arcangeli, B. Saracino, and M.G. Petrongari Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area Radiother Oncol 84 2007 148 155
27. L.P. Muren, E. Wasbo, and S.I. Helle Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: planning procedures and early experiences Int J Radiat Oncol Biol Phys 71 2008 1034 1041
28. A.A. Aizer, J.B. Yu, A.M. McKeon, R.H. Decker, J.W. Colberg, and R.E. Peschel Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma Int J Radiat Oncol Biol Phys 75 2009 1344 1349
29. R. McCammon, K.E. Rusthoven, B. Kavanagh, S. Newell, F. Newman, and D. Raben Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer Int J Radiat Oncol Biol Phys 75 2009 413 420
30. C. Deville, S. Both, W.T. Hwang, Z. Tochner, and N. Vapiwala Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer Int J Radiat Oncol Biol Phys 78 2010 763 772
31. J.B. Adkison, D.R. McHaffie, and S.M. Bentzen Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer Int J Radiat Oncol Biol Phys 82 2012 184 190
32. W.Y. Khoder, M. Trottmann, and A. Buchner Risk factors for pelvic lymphoceles post-radical prostatectomy Int J Urol 18 2011 638 643